Diagnostic and Prognostic Biomarkers in Parkinson Disease

NCT00653783 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2008-12-31

No results posted yet for this study

Summary

The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.

Conditions

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED
  • The Parkinson Study Group

    lead NETWORK

Principal Investigators

  • Bernard Ravina, MD · University of Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00653783 on ClinicalTrials.gov